SKP2/P27Kip1 pathway is associated with Advanced Ovarian Cancer in Saudi Patients

  • Hafez, Mohamed M (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Alhoshani, Ali R (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Al-Hosaini, Khaled A (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Alsharari, Shakir D (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Al Rejaie, Salim S (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Sayed-Ahmed, Mohamed M (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh) ;
  • Al-Shabanah, Othman A (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University Riyadh)
  • Published : 2015.09.02


Background: Ovarian cancer is the most common gynecological malignancy and constitutes the fifth leading cause of female cancer death. Some biological parameters have prognostic roles in patients with advanced ovarian cancer and their expression may contribute to tumor progression. The aim of this study was to investigate the potential prognostic value of SKP2, genes P27Kip1, K-ras, c-Myc, COX2 and HER2 genes expression in ovarian cancer. Materials and Methods: This study was performed on two hundred formalin fixed paraffin embedded ovarian cancer and normal adjacent tissues (NAT). Gene expression levels were assessed using real time PCR and Western blotting. Results: Elevated expression levels of SKP2, K-ras, c-Myc, HER2 and COX2 genes were observed in 61.5% (123/200), 92.5% (185/200), 74% (148/200), 96 % (192/200), 90% (180/200) and 78.5% (157/200) of cancer tissues, respectively. High expression of SKP2 and down-regulation of P27 was associated with advanced stages of cancer. Conclusions: The association between high expression of c-Myc and SKP2 with low expression of P27 suggested that the Skp2-P27 pathway may play an important role in ovarian carcinogenesis. Reduced expression of P27 is associated with advanced stage of cancer and can be used as a biological marker in clinical routine assessment and management of women with advanced ovarian cancer.


  1. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, et al (2005). Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res, 11, 4090-6.
  2. Carrano AC, Eytan E, Hershko A, et al (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol, 1, 193-9.
  3. Catzavelos C, Bhattacharya N, Ung YC, et al (1997). Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med, 3, 227-30.
  4. Cavalieri F, Goldfarb M (1987). Growth factor-deprived BALB/c 3T3 murine fibroblasts can enter the S phase after induction of c-myc gene expression. Mol Cell Biol, 7, 3554-60.
  5. Chay WY, Chew SH, Ong WS, et al (2013). HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One, 8, 61565.
  6. Coppola JA, Cole MD (1986). Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature, 320, 760-3.
  7. Cote RJ, Shi Y, Groshen S, et al (1998). Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst, 90, 916-20.
  8. Demir L, Yigit S, Sadullahoglu C, et al (2014). Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype? Asian Pac J Cancer Prev, 15, 9739-45.
  9. Erkinheimo TL, Lassus H, Finne P, et al (2004). Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/ neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res, 10, 538-45.
  10. Farley J, Fuchiuji S, Darcy KM, et al (2009). Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimallyresected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol, 113, 341-7.
  11. Felip E, Del Campo JM, Rubio D, et al (1995). Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer, 75, 2147-52.<2147::AID-CNCR2820750818>3.0.CO;2-8
  12. Ferrandina G, Ranelletti FO, Lauriola L, et al (2002). Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol, 85, 305-10.
  13. Frattini M, Saletti P, Romagnani E, et al (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, 97, 1139-45.
  14. Fredersdorf S, Burns J, Milne AM, et al (1997). High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A, 94, 6380-5.
  15. Akman A, Ciftcioglu MA, Ozbey C, et al (2008). Expression of cell cycle inhibitor p27Kip1 in nevi and melanomas. Indian J Dermatol Venereol Leprol, 74, 551.
  16. Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al (2005). Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol, 192, 819-25.
  17. Anglesio MS, Kommoss S, Tolcher MC, et al (2013). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol, 229, 111-20.
  18. Auersperg N, Wong AS, Choi KC, et al (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev, 22, 255-88.
  19. Baekelandt M, Holm R, Trope CG, et al (1999). Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res, 5, 2848-53.
  20. Baudino TA, Maclean KH, Brennan J, et al (2003). Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell, 11, 905-14.
  21. Ben-Izhak O, Akrish S, Gan S, et al (2009). Skp2 and salivary cancer. Cancer Biol Ther, 8, 153-8.
  22. Frontini M, Kukalev A, Leo E, et al (2012). The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment. Dev Cell, 23, 356-70.
  23. Gstaiger M, Jordan R, Lim M, et al (2001). Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A, 98, 5043-8.
  24. Haya S. Al-Eid MSM, Shouki Bazarbashi, Ali Al-Zahrani (2007). Cancer incidence and survival report Saudi Arabia.
  25. He JP, Hao Y, Wang XL, et al (2014). Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev, 15, 5967-76.
  26. Henriksson M, Luscher B (1996). Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res, 68, 109-82.
  27. Hogdall EV, Christensen L, Kjaer SK, et al (2003). Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the danish malova ovarian cancer study. Cancer, 98, 66-73.
  28. Hulit J, Lee RJ, Li Z, et al (2006). p27Kip1 repression of ErbB2- induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res, 66, 8529-41.
  29. Hung WC, Tseng WL, Shiea J, et al (2010). Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett, 288, 156-61.
  30. Johnson SM, Grosshans H, Shingara J, et al (2005). RAS is regulated by the let-7 microRNA family. Cell, 120, 635-47.
  31. Keller UB, Old JB, Dorsey FC, et al (2007). Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J, 26, 2562-74.
  32. Khalifeh I, Munkarah AR, Lonardo F, et al (2004). Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol, 23, 162-9.
  33. Kudo Y, Kitajima S, Sato S, et al (2001). High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res, 61, 7044-7.
  34. Lanitis E, Dangaj D, Hagemann IS, et al (2012). Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One, 7, 49829.
  35. Latres E, Chiarle R, Schulman BA, et al (2001). Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A, 98, 2515-20.
  36. Li JQ, Wu F, Masaki T, et al (2004). Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol, 25, 87-95.
  37. Lu M, Zhao Y, Xu F, et al (2012). The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med Oncol, 29, 3409-15.
  38. MacLachlan TK, Sang N, Giordano A (1995). Cyclins, cyclindependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr, 5, 127-56.
  39. Makrodouli E, Oikonomou E, Koc M, et al (2011). BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer, 10, 118.
  40. Malek NP, Sundberg H, McGrew S, et al (2001). A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature, 413, 323-7.
  41. Mannan A, Hahn-Stromberg V (2012). K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. APMIS, 120, 459-68.
  42. Martino T, Magalhaes FC, Justo GA, et al (2014). The pterocarpanquinone LQB-118 inhibits tumor cell proliferation by downregulation of c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle inhibitor expression. Bioorg Med Chem, 22, 3115-22.
  43. Missaoui N, Abdelkarim SB, Ayachi M, et al (2014). HER2 expression in ovarian mucinous carcinomas in Tunisia. Asian Pac J Cancer Prev, 15, 8121-5.
  44. Moroni M, Veronese S, Benvenuti S, et al (2005). Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 6, 279-86.
  45. Muller BM, Kronenwett R, Hennig G, et al (2011). Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol, 20, 1-10.
  46. O'Hagan RC, Ohh M, David G, et al (2000). Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev, 14, 2185-91.
  47. Ozols RF (1992). Ovarian cancer, part II: treatment. Curr Probl Cancer, 16, 61-126.
  48. Pan XH (2012). Pathway crosstalk analysis based on proteinprotein network analysis in ovarian cancer. Asian Pac J Cancer Prev, 13, 3905-9.
  49. Peter A, Heintz M (1996). Surgery in ovarian cancer: the concept of cytoreductive surgery. Curr Opin Obstet Gynecol, 8, 8-11.
  50. Poorolajal J, Jenabi E, Masoumi SZ (2014). Body mass index effects on risk of ovarian cancer: a meta- analysis. Asian Pac J Cancer Prev, 15, 7665-71.
  51. Roussel MF, Cleveland JL, Shurtleff SA, et al (1991). Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature, 353, 361-3.
  52. Seo SS, Song YS, Kang DH, et al (2004). Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol, 92, 927-35.
  53. Shi P, Zhang Y, Tong X, et al (2011). Dihydrotestosterone induces p27 degradation via direct binding with SKP2 in ovarian and breast cancer. Int J Mol Med, 28, 109-14.
  54. Shigemasa K, Gu L, O'Brien TJ, et al (2003). Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res, 9, 1756-63.
  55. Shintani S, Li C, Mihara M, et al (2003). Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncol, 65, 355-62.
  56. Slingerland J, Pagano M (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol, 183, 10-7.<10::AID-JCP2>3.0.CO;2-I
  57. Spruck C, Strohmaier H, Watson M, et al (2001). A CDKindependent function of mammalian Cks1: targeting of SCF (Skp2) to the CDK inhibitor p27Kip1. Mol Cell, 7, 639-50.
  58. Steelman LS, Chappell WH, Abrams SL, et al (2011). Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY), 3, 192-222.
  59. Steffensen KD, Waldstrom M, Jeppesen U, et al (2007). The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer, 17, 798-807.
  60. Sutterluty H, Chatelain E, Marti A, et al (1999). p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol, 1, 207-14.
  61. Vadlamudi R, Mandal M, Adam L, et al (1999). Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18, 305-14.
  62. Valeria Masciullo GF, Bruna Pucci, Francesco Fanfani, et al (2000). p27Kip1 Expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis1. Clin Cancer Res, 6, 4816-22.
  63. Verri E, Guglielmini P, Puntoni M, et al (2005). HER2/neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance. Clinical study. Oncol, 68, 154-61.
  64. Wang NN, Zhao LJ, Wu LN, et al (2013). Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line. Asian Pac J Cancer Prev, 14, 4983-8.
  65. Wang SC, Lien HC, Xia W, et al (2004). Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 6, 251-61.
  66. Wang Z, Fukushima H, Inuzuka H, et al (2012). Skp2 is a promising therapeutic target in breast cancer. Front Oncol, 1.
  67. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131, 18-43.
  68. Yang C, Sun JJ (2015). Mechanistic studies of cyclin-dependent kinase inhibitor 3 (cdkn3) in colorectal cancer. Asian Pac J Cancer Prev, 16, 965-70.
  69. Yang H, Xu W, Li Y, et al (2014). Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. Anticancer Drugs, 25, 767-77.
  70. Zhang Y, Peng Z, Qiu G, et al (2002). Overexpression of cyclin a in hepatocellular carcinoma and its relationship with HBx gene integration. Zhonghua Zhong Liu Za Zhi, 24, 353-5.
  71. Zhao YH, Wang T, Yu GF, et al (2013). Anti-proliferation effects of interferon-gamma on gastric cancer cells. Asian Pac J Cancer Prev, 14, 5513-8.

Cited by

  1. RIG-I inhibits pancreatic β cell proliferation through competitive binding of activated Src vol.6, pp.1, 2016,
  2. Nitidine chloride inhibited the expression of S phase kinase-associated protein 2 in ovarian cancer cells vol.16, pp.14, 2017,
  3. Expression of hsa-let-7b-5p, hsa-let-7f-5p, and hsa-miR-222-3p and their putative targets HMGA2 and CDKN1B in typical and atypical carcinoid tumors of the lung vol.39, pp.10, 2017,
  4. Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer vol.8, pp.1, 2018,